Search Results 221-230 of 17423 for Interferon

  1. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/​Refractory T-cell Non-Hodgkin Lymphoma - Mayo Clinic

    Relapsed or refractory (R/R) disease, after at least 1 prior treatment regimen as per disease staging (including but not limited to oral bexarotene, interferon ...

  2. A Study to Evaluate Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia - Mayo Clinic

    Prior therapy for myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN) (e.g., thalidomide or lenalidomide, interferon, jakafi, cytokines, 5 ...

  3. Publications - James P. Utz, M.D. - Mayo Clinic

    2004 May; 127(5):1350-60. View PubMed; Kalra S, Utz JP, Ryu JH, Mayo Clinic Interstitial Lung Diseases Group. Interferon gamma-1b therapy for advanced ...

  4. A Study to Evaluate if Benralizumab Compared to Mepolizumab May be Beneficial in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) - Mayo Clinic

    ... interferon-α or alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor therapy within 12 weeks prior to screening or an ...

  5. Captopril (oral route) - Side effects & dosage - Mayo Clinic

    Interferon Alfa-2a; Irbesartan; Lefamulin; Levoketoconazole; Lithium; Loperamide; Losartan; Mavorixafor; Melphalan; Mercaptopurine; Methotrexate; Morphine ...

  6. A Study to Evaluate Aspirin for Treating Multiple Sclerosis-related Fatigue - Mayo Clinic

    Beta-interferon, glatiramer acetate, immunosuppressant drugs (mitoxantrone, azathioprine, etc.) are permitted if a stable dose has been used for greater ...

  7. Dupilumab Treatment on Sinonasal Respiratory Symptoms and Sense of Smell in Ethnically Diverse Patients with Chronic Rhinosinusitis and Nasal Polyps - Mayo Clinic

    ... interferon-γ:interleukin-4 ratio consistent with an in vivo Th1 bias. Furthermore, iNKT cells from SEB-injected HLA-DR4-transgenic mice, and iNKT cells from ...

  8. (HARBOR) Study To Evaluate Efficacy And Safety Of BLU-263 Versus Placebo In Patients With Indolent Systemic Mastocytosis - Mayo Clinic

    ... interferon alpha, pegylated interferon, or antibody therapy < 28 days or 5 half-lives of the drug (whichever is longer), before beginning the screening ...

  9. A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma - Mayo Clinic

    Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-2 [aldesleukin]) within 6 weeks prior to cycle ...

  10. Publications - Yul W. Yang, M.D., Ph.D. - Mayo Clinic

    ... interferon-gamma locus. Cell. 2013 Feb 14; 152 (4):743-54. View PubMed; Turner PE, McBride RC, Duffy S, Montville R, Wang LS, Yang YW, Lee SJ, Kim J ...